BIOMM S.A.
http://www.biomm.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From BIOMM S.A.
Biocon And Biomm Team Up In Brazil On Ozempic Rival – With Potential Near-Term Launch
India’s Biocon Limited has struck an exclusive deal for a generic version of semaglutide in Brazil with local player Biomm. And a recent court ruling means that launch could come sooner rather than later for the Ozempic rival.
Generic Spiriva Delivers First Mover Advantage In US, Lupin Plans Europe Launch
Lupin’s Q2 margins jumped post launch of the first Spiriva generic in the US, encouraging launch plans for Europe and Canada. With four out of five plants clearing a regulatory overhang from earlier warning letters, the specialty engine is revving up though competition in first-to-file products launched earlier could dampen margins somewhat.
gSpiriva Delivers First Mover Advantage In US, Lupin Plans Europe Launch
Lupin’s Q2 margins jumped post launch of the first Spiriva generic in the US, encouraging launch plans for Europe and Canada. With four out of five plants clearing a regulatory overhang from earlier warning letters, the specialty engine is revving up though competition in first-to-file products launched earlier could dampen margins somewhat
Bio-Thera And Biomm Widen Biosimilar Alliance In Brazil
China’s Bio-Thera Solutions is continuing to pen deals offloading commercialization rights outside of its domestic market to for its BAT2206 biosimilar Stelara (ustekinumab) candidate, this time with Biomm in Brazil.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Savicevic Participacoes SA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice